Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Down 5.2% – Should You Sell?

Fresenius SE & Co. (OTCMKTS:FSNUY)’s share price fell 5.2% on Friday . The company traded as low as $11.22 and last traded at $11.22. 49,496 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 104,004 shares. The stock had previously closed at $11.84.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FSNUY. Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. has a consensus rating of “Buy”.

Fresenius SE & Co. Trading Down 4.0%

The company has a quick ratio of 1.00, a current ratio of 1.32 and a debt-to-equity ratio of 0.47. The firm has a market cap of $25.62 billion, a price-to-earnings ratio of 15.16 and a beta of 0.68. The business’s fifty day moving average is $12.48 and its two-hundred day moving average is $13.76.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to analyst estimates of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.29%. Equities analysts anticipate that Fresenius SE & Co. will post 1.05 earnings per share for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.